Simulated Clinical Use Testing On Safety Lancets (Test B)
Study Details
Study Description
Brief Summary
A simulated clinical use testing on the HTL-Strefa's safety lancets
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
This study aims to evaluate the safety of the use of the safety lancets: Haemolance Plus, Prolance and MediSafe Solo in the prevention of NSI and to evaluate the user's opinion with regards to the handling characteristics of the medical devices.
The simulated use clinical study will involve healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: simulation of skin pricking type 420 The evaluator simulated the capillary blood sampling with the safety lancet type 420 |
Device: Haemolance Plus safety lancet
Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
|
Experimental: simulation of skin pricking type 430 The evaluator simulated the capillary blood sampling with the safety lancet type 430 |
Device: Prolance safety lancet
Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
|
Experimental: simulation of skin pricking type 520 The evaluator simulated the capillary blood sampling with the safety lancet type 520 |
Device: MediSafe Solo safety lancet
MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
|
Outcome Measures
Primary Outcome Measures
- The true failure rate of the tested devices [At time of testing, up to 90 minutes]
- Effectiveness of the safety lancet's sharps injury prevention features [At time of testing, up to 90 minutes]
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
Secondary Outcome Measures
- Subjective assessments regarding evaluators' interactions with the tested safety lancets [At time of testing, up to 90 minutes]
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
- Safety of the devices based on the evaluators' assessments (five-point response scale) [At time of testing, up to 90 minutes]
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure any and all observed needlestick injuries and device malfunctions. Numbers assigned to Likert scale express a "greater than" relationship.
- Various aspects of the ease of use. [At time of testing, up to 90 minutes]
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
- Any handling, usability questions / issues associated with the device [At time of testing, up to 90 minutes]
Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.
Eligibility Criteria
Criteria
Inclusion Criteria:
The inclusion criteria for HCP and lay person evaluators have been chosen based on FDA guidance:
-
evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts)
-
evaluators will be United States (US) residents
-
evaluators can read, write, and speak English
-
evaluators are at least 18 years old
-
evaluators are able to understand and provide signed consent for the study
-
evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
-
evaluators have no concerns about the ability to perform the simulated skin pricking.
Exclusion Criteria:
Individuals will be excluded if:
-
They do not routinely use safety lancets to collect capillary blood samples,
-
They cannot read, write, and speak English,
-
They or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
-
They have participated in a product evaluation
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | UL LLC | Chicago | Illinois | United States | 60606 |
2 | Schlesinger Associates | Boston | Massachusetts | United States | 02116 |
Sponsors and Collaborators
- HTL-Strefa S.A.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Test B